Navigation Links
Study Shows MS Patients at Most Risk for Drug-Linked Brain Illness
Date:5/16/2012

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, May 16 (HealthDay News) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Even the multiple sclerosis patients at highest risk of developing the brain infection face low odds of getting it while on Tysabri, but the infection can be deadly.

"Now we can identify which risk group each patient is in. This will help doctors and patients make better decisions," said Dr. Gary Bloomgren, lead author of a study released Wednesday and vice president of drug safety at Biogen Idec, which makes the drug.

About 100,000 patients have taken Tysabri at least once. The drug, which is used mainly to delay the progression of multiple sclerosis, has been on the market since 2006. It originally went on the market in 2005 but was removed due to medical problems that some patients encountered, Bloomgren said.

Tysabri is expensive, costing about $40,000 a year. It dampens the immune system, potentially reducing the inflammation that is a major part of multiple sclerosis. Dampening the immune system, however, can allow an infection known as the JC virus to wreak havoc on the brain and cause a condition called progressive multifocal leukoencephalopathy.

The JC virus is extremely common, affecting about half of adults by middle age, but the immune system normally keeps it under control so it causes no symptoms. If unleashed, however, progressive multifocal leukoencephalopathy can cause cognitive problems, such as unusual behavior, paralysis and problems with vision, speech and balance, said study co-author Dr. Sandra Richman, senior medical director at Biogen Idec.

Once the symptoms appear, doctors usually advise patients to stop the treatment, she said. Progressive multifocal leukoencephalopathy often causes permanent disability, and can be deadly.

In 2010, the U.S Food and Drug Administration added a new warning about the rare brain infection to Tysabri's label. The drug also is used to treat Crohn's disease.

In January, the FDA approved a test to determine the risk of brain infection in Tysabri users.

In the new study, the researchers examined various statistics to figure out which multiple sclerosis patients were at highest risk of progressive multifocal leukoencephalopathy if they take Tysabri. Blood samples of nearly 5,900 patients with multiple sclerosis were analyzed.

Just more than 1 percent of patients showed signs of exposure to the JC virus, had taken immune-suppressing drugs before Tysabri and had been on Tysabri for 25 to 48 months.

The risk for those who hadn't been exposed to the JC virus was 120 times smaller at 0.009 percent.

Patients who worry about progressive multifocal leukoencephalopathy "may think about it differently because of the low risk in that subgroup of patients," Bloomgren said.

Multiple sclerosis patients who have been exposed to the JC virus but haven't taken immune-suppressing drugs while on Tysabri may choose to continue taking the drug, said Dr. Scott Zamvil, a professor of neurology at the University of California-San Francisco.

"Patients who are on the drug don't want to come off because it's that potent of a drug," he said. "It is the most potent of the currently approved drugs."

Patients need to talk to their physicians and weigh the benefit of the medication versus the potential risk, Zamvil said.

The study appears in the May 17 issue of the New England Journal of Medicine.

More information

For more about multiple sclerosis, try the U.S. National Library of Medicine.

SOURCES: Gary Bloomgren, M.D., vice president of drug safety, and Sandra Richman, M.D., senior medical director, Biogen Idec, Cambridge, Mass.; Scott Zamvil, M.D., professor of neurology, University of California-San Francisco; May 17, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Links Antibiotic to Slight Rise in Heart Patients Death Risk
2. U.S. Assistance to Africa Cut AIDS-Related Deaths: Study
3. Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study
4. Inhaled Steroids Lead to Big Drop in Asthma Deaths at Texas Hospital: Study
5. New inflammation hormone link may pave way to study new drugs for Type 2 diabetes
6. Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment
7. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
8. Study examines BI-RADS and MRI in predicting breast cancer
9. Self-Managing COPD Might Pose Risks, Study Suggests
10. Study finds number of battery-related emergency department visits by children more than doubles
11. UTSA study finds ovulating women perceive sexy cads as good dads
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Shows MS Patients at Most Risk for Drug-Linked Brain Illness
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology: